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Abstract
Spinocerebellar ataxia type 7 is a polyglutamine disorder caused by an expanded CAG repeat mutation that results in
neurodegeneration. Since no treatment exists for this chronic disease, novel therapies such post-transcriptional RNA
interference-based gene silencing are under investigation, in particular those that might enable constitutive and tissue-
specific silencing, such as expressed hairpins. Given that this method of silencing can be abolished by the presence of
nucleotide mismatches against the target RNA, we sought to identify expressed RNA hairpins selective for silencing the
mutant ataxin-7 transcript using a linked SNP. By targeting both short and full-length tagged ataxin-7 sequences, we show
that mutation-specific selectivity can be obtained with single nucleotide mismatches to the wild-type RNA target
incorporated 39 to the centre of the active strand of short hairpin RNAs. The activity of the most effective short hairpin RNA
incorporating the nucleotide mismatch at position 16 was further studied in a heterozygous ataxin-7 disease model,
demonstrating significantly reduced levels of toxic mutant ataxin-7 protein with decreased mutant protein aggregation and
retention of normal wild-type protein in a non-aggregated diffuse cellular distribution. Allele-specific mutant ataxin7
silencing was also obtained with the use of primary microRNA mimics, the most highly effective construct also harbouring
the single nucleotide mismatch at position 16, corroborating our earlier findings. Our data provide understanding of RNA
interference guide strand anatomy optimised for the allele-specific silencing of a polyglutamine mutation linked SNP and
give a basis for the use of allele-specific RNA interference as a viable therapeutic approach for spinocerebellar ataxia 7.
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Introduction
Spinocerebellar ataxia 7 (SCA7) is a late onset neurodegener-
ative disease which presents with a classic autosomal dominant
ataxia but which is uniquely associated with macular degeneration
[1]. It is part of a group of nine known polyglutamine (polyQ)
disorders which share expanded (CAG) repeat mutations that
translate into polyQ tracts [2]. While it is considered one of the
rarer dominant inherited ataxias, in South Africa it is the second
most prevalent of the autosomal dominant cerebellar ataxias [3].
Removal of accumulated mutant polyQ proteins has been shown
to ameliorate the disease phenotype in mouse [4] and drosophila
models [5], which is consistent with a toxic gain-of-function
disease mechanism [6]. However, some studies report that wild-
type protein function may be affected by the presence of the
mutant resulting in an additional loss-of-function mechanism
contributing to disease pathogenesis [7–9]. Most RNA interfer-
ence (RNAi)-based therapeutic approaches to suppress the
expression of toxic polyQ proteins have been demonstrated in
mouse models of polyQ disorders, including SCA1, SCA3 and HD
[10–12]. While important, these studies have targeted suppression
of the human disease transgene in the mouse and therefore have
not investigated the effects of concomitant wild-type allele
suppression or investigated the mechanistic basis for specific
suppression of polyQ disease alleles.
The sequence-specific nature of post-transcriptional RNAi has
therapeutic potential where selective inhibition of a mutant
transcript would leave the wild-type intact for normal cellular
function [13,14]. This can be achieved by exploiting an
endogenous single base pair difference between the wild-type
and mutant transcripts, such that an effective RNAi sequence can
be designed with complete homology to the mutant transcript but
containing a single nucleotide mismatch with respect to the wild-
type. Effective double-stranded RNAi sequences, whether small
interfering RNAs (siRNAs) or derived from expression of hairpin
RNAs (shRNAs), undergo strand selection to generate an active
single-stranded guide sequence incorporated into the RISC
complex. This 19–24 nucleotide guide strand comprises functional
domains, including the seed region nucleotides 2–8 for target
recognition and central nucleotides 10 and 11 for Ago2-mediated
cleavage. An important question therefore is which guide strand
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positions are least tolerant of the presence of a destabilising
nucleotide mismatch and therefore how guide strand anatomy can
be optimised for mutation-specific silencing
Previous studies have shown degrees of target discrimination with
the single nucleotide mismatch incorporated at central guide strand
positions [15,16]. Subsequently, using an extensive panel of siRNAs,
Schwarz and colleagues demonstrated that mismatches 39 to the
centre of the guide strand had increased selectivity against
huntingtin and SOD1 targets [17]. Furthermore, this study showed
that purine:purine nucleotide mismatches resulted in maximum
selectivity, whereas purine:pyrimidine and in particular the weak
G:U mismatch (in which a single hydrogen bond is formed between
the two nucleotides) yielded significantly less discrimination, a
finding suggested in earlier studies [18–21]. Other investigations
have used the mutation itself to discriminate between mutant and
wild-type transcripts [22,23], and although structural differences
between polyQ transcripts may make this a feasible approach in
theory [24] it is not ideal given the potential off-target effects of a
CAG repeat sequence [14,25]. However, a common SNP (located
in the 39 region of atxn7, NM000333.3) linked to the SCA7 mutation
has been identified, such that over 50% of South African SCA7
patients have the ‘A’ and ‘G’ alleles associated with the mutant and
wild-type transcripts respectively [26]. Targeting of this SNP allows
detailed study of how guide strand anatomy can be optimised for
single nucleotide specific silencing and whether this could form the
basis of a potential therapy for SCA7.
Results
shRNAs targeting ataxin-7 with effective single
nucleotide discrimination
In order to identify effective post-transcriptional RNAi
sequences targeting the atxn7 linked SNP, multiple short hairpin
RNAs (shRNAs) were screened, each incorporating the weak G:U
mismatch created by the targeted SNP with respect to the wild-
type transcript successively at positions 10 to 16 from the 59 end of
the active shRNA guide sequence (Figure 1A). These shRNAs
were screened in an assay in which a short 60 bp target of either
the mutant or the wild-type ataxin7 gene sequence was inserted in
the 39UTR of Renilla luciferase and normalised to background
Firefly luciferase (Figure 1B). Nucleotide mismatches incorporated
at shRNA positions 11-16 all showed effective discrimination
between the wild-type and mutant targets (Figure 2A), shR-P15
demonstrating the greatest discrimination with the wild-type target
minimally affected retaining 90% expression and the mutant
knocked down to nearly 50% relative to a non-specific shRNA
control (p,0.05). However, overall target knockdown was less
efficient than for shR-P12 (wild-type and mutant targets knocked
down to 40% and 20% respectively) and shR-P14 (wild-type and
mutant targets knocked down to 45% and 20% respectively).
Interestingly, the shR-P16 construct showed little mutant-specific
discrimination, knocking down both wild-type and mutant targets
with high efficiency (20% and 10% remaining of the wild-type and
mutant targets), and indicating high tolerance of the single
nucleotide mismatch incorporated at this predicted shRNA guide
strand position. Given the weak nature of the atxn7 G:U nucleotide
mismatch, we investigated whether enhanced wild-type:mutant
discrimination could be achieved by incorporating a range of
secondary mismatches in addition to the primary nucleotide
mismatch (Figure 1A), however improved mutant selectivity was
not obtained (Figure S1A). It was noted that the inclusion of
secondary mismatches resulted in decreased levels of knockdown
at almost all positions tested indicating that the secondary
mismatch ablated efficient RNAi against both targets.
Effective shRNA-mediated silencing of full-length mutant
atxn7
Given that the initial data shown (Figures 2 and Figure S1A)
and that obtained by others [17] was acquired from screens of
short target mRNA sequences, we sought to model the
endogenous SCA7 disease more closely by studying shRNAs
targeting the full-length endogenous atxn7 cDNA transcript
(Figure 3). This assay was validated using an shRNA specific for
the GFP sequence (shR-E19) which consistently showed 80%
silencing efficiency. Using a full length atxn7 target transcript fused
to an eGFP reporter target, knockdown was found to be reduced
across the panel of shRNAs studied (Figure 3). Again, shRNAs
incorporating the single nucleotide mismatches at position 12
showed some mutant selectivity (wild-type and mutant targets knocked
down to 70% and 50% respectively), however shR-P15 – the most
discriminatory shRNA in the dual luciferase assay against the short
target transcript – showed no ability to knockdown either the full-
length mutant or wild-type atxn7 gene (Figure 3). Interestingly,
shR-P16, which showed the most effective knockdown against
both short targets in the luciferase assay, demonstrated the greatest
selectivity against the full-length mutant target with 90% of wild-
type and 50% of mutant expression remaining (p,0.05). Again,
none of the double nucleotide mismatched shRNA hairpins
showed any significant mutant selectivity against the full-length
atxn7 target (Figure S1B). The selective shR-P16 was further
studied by testing whether enhanced discrimination was possible
by incorporating further modifications within this shRNA guide
strand, including shifting the position of the secondary mismatch
and the inclusion of additional mismatches (Figure S2A). None of
the further modified position 16-based shRNA sequences showed
either significant knockdown or improved mutation-specific
selectivity (Figure S2B), and therefore further analysis of only the
most efficacious shR-P16 construct was undertaken.
Effective silencing of mutant atxn7 in a heterozygous
SCA7 disease model
To more closely mimic the endogenous SCA7 disease state, a
heterozygous model was established in which both full-length wild-
type and mutant atxn7 cDNA expression plasmids were co-
transfected into HEK293 cells (Figure 1B). shR-P16, which
previously demonstrated high efficiency target selection in the
full-length hemizygous assay, again showed high mutation-specific
selectivity in the heterozygous disease model system, efficiently
knocking down the mutant transcript to 7% of control levels
(p,0.05) whilst minimally affecting the wild-type (74% of the
control levels; Figure 4). Note that the GFP specific shRNA (shR-
E19) control showed specificity for the GFP tagged wild-type
transcript and not the dsRED tagged mutant transcript.
To exclude the possibility that sequence specific effects of shR-P16
were influenced by the particular reporter tag used, experiments were
conducted utilizing the dsRED tag in a hemizygous assay. Silencing
levels of 30% were obtained (Figure S4) which are similar to that
obtained with the GFP tagged transcript, confirming that the sequence
specificity of shR-P16 was independent of the reporter tag used
(Figure 3). Moreover, the sequence specificity of the shR-P16 was not
significantly affected by a change in the number of repeats; the G allele
of the SNP being resistant to silencing in the presence of either 10 or
100 CAG repeats (Figure 3 and Figure S4).
shRNA P16 targeting mutant atxn7 corrects the SCA7
cellular phenotype
It is well documented that mutant polyQ proteins form
intracellular aggregates which are associated with, if not directly
RNAi-Based Silencing of SCA7
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7232
causative of, disease pathogenesis [27]. In addition, it has been
shown that mutant ATXN7 protein recruits wild-type ATXN7
into intracellular inclusion-like aggregates [28]. In our studies,
confocal microscopy showed that while the mutant protein
(CAG100) forms large distinct aggregates, expression of the wild-
type protein (CAG10) alone resulted in minimal aggregate
formation (Figure 5A). However, heterozygous co-expression of
both wild-type and mutant atxn7 genes reproduces previous reports
[28] in which the wild-type ATXN7 protein is found to co-localize
with aggregates of mutant protein (Figure 5Bi–iii). Transfection of
mutation-specific shR-P16 into these cells resulted not only in
decreased numbers of cells with mutant protein aggregates, but
also in wild-type protein normalised to a non-aggregated, more
diffuse pattern of cellular localisation seen when the wild-type is
transfected alone and typical of the non-disease state (Figure 5Biv–
vi). To quantify these findings, the number of cells containing
detectable aggregates or showing a dispersed pattern of wild-type
protein localisation was determined following shR-P16 treatment
and compared to that seen with the non-specific control
(Figure 5C). This data shows a highly significant decrease in the
number of cells expressing mutant protein aggregates in the
presence of shR-P16, corroborating data from the fluorescent
heterozygous assay. More importantly, these results further
support the original observation that, not only does expression
of both mutant and wild-type protein result in a significantly
increased percentage of aggregates containing wild-type protein
(p,0.05), but that treatment with shR-P16 promotes restoration of
the wild-type protein expression pattern.
Figure 1. RNAi-based shRNAs and target vectors designed for atxn7 knockdown. (A) Convention for the diagram follows Schwarz and
colleagues (16). Sequences of expected single and double mismatch guide strands (underlined) processed from an shRNA format indicating the site
of the primary mismatch to the G allele of the wild-type atxn7 target. Sequence context of both the wild-type and mutant targets are shown.
Functional asymmetry was induced by creating G:U mis-pairings in the 39 end of the anti-guide strand; these are highlighted in bold. The shRNAs
were labelled according to the position of the primary mismatch relative to the 59 end of the guide strand; followed by any additional mismatches.
The nomenclature is based on a 21bp guide strand after cleavage of the anti-sense strand by Dicer. (B) Schematic representations of the fused target-
reporter cassettes. atx7-G-luc and atx7-A-luc are the wild-type and mutant reporter siCHECK plasmids used in the luciferase assay, and included a
short region of 60 bp of atxn7 target sequence spanning the SNP fused to the Renilla luciferase reporter gene. atx7-10-G-eGFP, atx7-100-A-eGFP,
atx7-100-A-DsRED are the 3 reporter plasmids used in the full-length hemi- and heterozygous assays and consist of the full-length atxn7 cDNA. The
wild-type construct (atx7-10-G-eGFP) has a CAG repeat length of 10 incorporating the G allele of the SNP, fused to eGFP. The two mutant constructs
(atx7-100-A-eGFP, atx7-100-A-DsRED) have CAG repeat lengths of 100, as well as the A allele of the SNP, and are fused to eGFP and DsRED
respectively.
doi:10.1371/journal.pone.0007232.g001
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Effective mutation-specific silencing with a primary
microRNA mimic
Primary miRNA mimics have advantages as gene silencing
agents since they permit tissue specific regulation and are
processed efficiently to yield physiological levels of the active
guide strand [29,30,31]. We therefore sought to design a series of
primary microRNA (pri-miRNA) mimics targeting mutant atxn7
that incorporated single nucleotide mismatches at successive
positions tiled across the active strand of a pri-miRNA. Multiple
pri-miRNA designs were generated (pri-miRNA hairpin structures
shown in Figure 6A), all based on the miR-122 pri-miRNA which
is known to yield homogenous mature miRNA species following
Drosha and Dicer processing [32]. In this study miR-P16 was
found to be the most effective pri-miRNA, demonstrating highly
effective mutation-specific atxn7 silencing in both the hemizygous
situation and in the heterozygous cellular model (Figures 6B and
Figure S3). Indeed, our data shows that miR-P16 provided
comparable levels of knockdown against the mutant and wild-type
Figure 2. Analysis of series of single mismatched shRNA guide sequences targeting the G.A SNP in atxn7 in a dual luciferase assay.
Relative levels of Renilla luciferase (hRluc) expression normalized to firefly luciferase (hFluc) expression for single mismatches (guide sequences shown
in Figure 1A). Each experiment was performed in triplicate and the data is relative to that measured using a non-specific shRNA, shR-NS.
Average6standard deviation is shown. Statistically significant differences (p,0.05) between wild-type and mutant silencing are indicated by
corresponding p values. Relative expression of wild-type and mutant targets is represented by red and blue bars respectively.
doi:10.1371/journal.pone.0007232.g002
Figure 3. Single mismatched shRNAs targeting the atxn7 G.A SNP in a full-length hemizygous assay. Quantitation of fluorescence in
HEK293 cells transfected with wild-type (atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and the indicated shRNA is shown. Each
experiment was performed in triplicate and the data is relative to that measured using a non-specific shRNA, NS. The shR-E19 hairpin was pE19; a
published U6/shRNA expression plasmid targeting eGFP (37). Average6standard deviation is shown. Statistically significant differences (p,0.05)
between wild-type and mutant silencing are indicated by corresponding p values. Wild-type and mutant targets are represented by red and blue bars
respectively.
doi:10.1371/journal.pone.0007232.g003
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atxn7 transcripts as was found for the shR-P16 hairpin, with almost
complete ablation of mutant atxn7 expression (to less than 10% of
control levels) with a minimal effect on the wild-type target
(retaining 75% expression; Figure 6B). This corroborates the
earlier data with respect to the position of the single nucleotide
mismatch within the shRNA guide strand for optimal silencing of
the atxn7 mutant transcript. In addition, an siRNA with the
mismatch as position 16 (siR-P16), shows discrimination (levels of
target remaining are 55% and 30% of the wild-type and mutant
respectively; Figure S5). This indicates that despite the additional
processing required of the pri-miRNA, the same miR-P16 active
strand sequence is likely to have been produced as that generated
by shR-P16.
While toxicity due to interference with RNAi pathway functions
is difficult to measure in vitro using standard cell toxicity assays,
competition studies comparing the effects of shRNA vs miRNA
based hairpins can be used to detect inhibitory effects on the post-
transcriptional RNAi machinery [33]. Increasing concentrations of
shR-P16 leads to a reduction in knockdown efficiency of the
reporter gene GFP by a GFP specific hairpin (Figure 6C). The
addition of 0.5 mg followed by 1 mg of shR-P16 leads to nearly
20% reduction in silencing of GFP (p,0.03). In contrast, the
corresponding miRNA hairpin (miR-P16) shows no such reduc-
tion in knockdown efficiency of GFP over the same concentration
range.
Discussion
Post-transcriptional RNAi-based gene silencing has potential for
the targeted silencing of disease mutations. In this study we have
systematically studied RNAi hairpin design and how hairpin guide
strand anatomy might be optimised for discriminating single
nucleotide mismatches in the atxn7 gene. Exploiting a CAG
mutation-linked SNP we investigated allele-specific silencing of
short and full-length atxn7 target sequences in both hemizygous
and heterozygous model systems, the latter mimicking aspects of
this dominant neurodegenerative disease. While analysis of short
atxn7 targets revealed that RNAi hairpins incorporating nucleotide
mismatches 39 to the central region were most selective for mutant
atxn7 silencing, this approach was not predictive of the most
efficacious hairpin for full-length target silencing. The hemizygous
and heterozygous full-length atxn7 model systems both revealed
the importance of hairpins with the nucleotide mismatch predicted
to be incorporated at the 39 position 16, and in the heterozygous
system this shRNA yielded over 90% mutant silencing. Moreover,
treatment with shR-P16 led to phenotype correction in a cellular
SCA7 model. The accuracy of the position 16 mismatch was
corroborated by subsequent analysis in which a pri-miRNA based
on miR-122 containing position 16 nucleotide mismatches also
generated highly efficient allele-specific atxn7 silencing.
The use of short mRNA targets fused to luciferase reporters is
an efficient strategy to identify optimal siRNA sequences for target
silencing [34,35]. Schwarz et al. [17] utilised this approach
extensively to screen siRNAs for the targeted silencing of mutant
Htt and SOD1 genes and reported that nucleotide mismatches in
the 39 region of the siRNA guide strand could allow greater single
nucleotide selectivity than those placed centrally, in particular
mismatches at position 16. The present study used a similar
approach in which a 60 nucleotide atxn7 target sequence was fused
to a luciferase reporter and systematically identified the impor-
tance of single nucleotide mismatches placed at specific positions
39 to the central position 10, in particular position 15, for efficient
mutation-specific silencing (Figure 2). However, the mismatch at
position 16 failed to show mutant discrimination with strong
silencing of both mutant and wild-type short target sequences.
This supports the general findings of Schwarz et al. in revealing
that the significance of the 39 region for single nucleotide
discrimination extends to expressed RNAi hairpins, however
importantly this data was not predictive of the most efficacious
shRNA targeting full-length mutant atxn7. That the shR-P15 was
most discriminatory for silencing of a short atxn7 target (and not
position 16 as shown by Schwarz et al. 2006), could simply be due
Figure 4. Knockdown of targets in a heterozygous assay using shRNAs. Quantification of fluorescence in HEK293 cells co-transfected with
wild-type atx7-10-G-eGFP and mutant atx7-100-A-DsRED expression plasmids and the indicated shRNA is shown. Each experiment was performed in
triplicate and the data is relative to that measured using a non-specific shRNA, NS. Average6standard deviation is shown. The shR-E19 hairpin was
pE19; a published U6/shRNA expression plasmid targeting eGFP (37). Statistically significant differences (p,0.05) between wild-type and mutant
silencing are indicated by using the one-tailed t-test. Wild-type and mutant targets are represented by green and red bars respectively.
doi:10.1371/journal.pone.0007232.g004
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to sequence context and the nature of the nucleotide mismatch in
this case. Despite extensive modifications designed to thermody-
namically bias shRNA guide strand selection (Figure 1A) it is
possible that strand selection by RISC may have affected shR-P15
knockdown efficiency [36,37], however it is unlikely that this
would have influenced the degree of discrimination.
In general target knockdown efficiency was diminished from the
luciferase assay to the full-length target studies, and shR-P15
which had previously shown the highest level of mutant selectivity
against the short target sequence failed to knockdown the full-
length mutant target (Figures 3 and 4). However, in both
hemizygous and heterozygous full-length target studies the shR-
P16 showed strong mutant selectivity with minimal effect against
the wild-type. The case of shR-P15 highlights the importance of
screening full length target sequences. While shR-P15 showed
good mutant selectivity against a short target sequence it was
ineffective against a longer full length sequence, a finding likely to
be explained by structural constraints imposed by the longer
mRNA sequence, given that full-length mRNA secondary
structure can influence the efficiency of RISC-associated cleavage
[38]. Thus, the data suggest that screening of short mRNA targets
might not be a reliable method for identifying optimal mutation-
Figure 5. Investigation of aggregate formation. (A) Representative confocal images of cells transfected with (i, ii) mutant (atx7-100-A-DsRED)
alone; (iii, iv) wild-type (atx7-10-G-eGFP) alone. (i) Image visualized under red fluorescence, (ii) red fluorescence merged with the bright field, (iii)
green fluorescence, and (iv) green fluorescence merged with the bright field. (B) Representative confocal images of cells co-transfected with wild-
type and mutant expression plasmids in addition to (i–iii) shR-NS or (iv–vi) shR-P16. (i) and (iv) show images under green fluorescence to reveal wild-
type protein, (ii) and (v) show images under red fluorescence to reveal mutant protein, and (iii) and (vi) show images then merged under green and
red fluorescence and bright field. Scale bar represents 10 mm. C. Cells expressing eGFP and/or DsRED were counted according to whether they
contained aggregates or a dispersed pattern of expression of mutant and wild-type ataxin-7. Cells were transfected with wild-type target (atx-10-G-
eGFP) alone; mutant target (atx7-100-A-DsRED) alone; mutant (atx7-100-A-DsRED), wild-type (atx-10-G-eGFP) and shR-NS (non-specific shRNA);
mutant, wild-type and shR-P16. Cells were counted separately in the red and the green filter by collecting 3 representative images from each well and
combining the total number. This was performed for each indicated combination in biological triplicate, yielding standard deviations. The bars
comprise the total number of cells counted in each transfection; separated according to whether they contained aggregates (blue) or a dispersed
pattern of expression (grey). Note that the decrease in expression from target vectors transfected alone to co-transfected cells is due to a promoter
occlusion effect of co-expression of targets and not due to the addition of shR-NS which has no effect upon the target vectors (data not shown).
Statistically significant differences in % of aggregate containing cells are indicated by corresponding p values.
doi:10.1371/journal.pone.0007232.g005
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specific RNAi hairpins (or siRNAs) for in vivo/clinical use. To
corroborate the shRNA data a second approach utilising a pri-
miRNA hairpin sequence was investigated. The miR-122
backbone was selected for these experiments given that it has
been demonstrated to yield homogenous guide strand sequences as
opposed to the more heterogeneous products from miR-31 [32].
Particular effort was made to replicate the thermodynamic
structure of miR-122 and wherever possible similar strength
mismatches were maintained. Importantly miR-P16 (designed to
place the nucleotide mismatch against the wild-type atxn7 at the
same position as was used in shR-P16) showed the greatest mutant
selectivity in both full-length cell-based assays, with very similar
mutant discrimination to that seen for the corresponding shRNA,
corroborating the earlier data (Figure 6, and Figure S3). These
data support the conclusion that the hairpins generated active
guide strands with the mismatch at position 16. In vivo studies have
shown that over expression of shRNA may lead to toxicity [30].
Although this phenomenon may be resolved by different shRNAs
and/or reducing their transcription, expression of miRNA-based
hairpins offer an attractive alternative [33,39]. Our results suggest
that use of miRNA shuttles may confer some advantage over the
shRNA design. This is supported by our observation that that
miR-P16 showed no apparent disruption of endogenous post-
transcriptional silencing, which was in contrast to what was
observed with the shR-P16 expression cassette.
The shR-P16 allowed phenotype correction in a cellular SCA7
model system, resulting in decreased levels of both mutant and
wild-type ATXN7 aggregates. While the reduction in mutant
aggregates correlated with a reduction in mutant protein
expression, the decrease in wild-type aggregates correlated with
an increase in the number of cells showing a dispersed pattern of
wild-type ATXN7 protein expression. This is important for two
reasons. First, some studies suggest that mutant aggregate
formation is protective and thus inhibition of aggregate formation
may have detrimental effects [40]. In the present study the
prevention of large aggregate formation occurred together with
reduction in the level of toxic mutant protein and thus is very likely
to be beneficial. Second, it has been reported that mutant ATXN7
protein recruits the wild-type protein into intracellular aggregates
[28] and thus pathogenesis in this polyQ disease may include an
Figure 6. Knockdown of targets using pri-miRNA-based hairpins. A) Guide strands in pri-miRNA format, with sequences of mismatch guide
strands processed from a miRNA format indicating the site of the primary mismatch to the G allele of the wild-type atxn7 target. Sequence context of
both the wild-type and mutant targets are shown. The miRNAs were labelled according to the position of the primary mismatch relative to the 59 end
of the guide strand. Major species refers to the strand most likely to be incorporated by RISC, while the minor species indicates the strand less likely
to be incorporated. B) Knockdown of targets in a heterozygous assay using miRNAs. Quantification of fluorescence in HEK293 cells co-transfected
with wild-type atx7-10-G-eGFP and mutant atx7-100-A-DsRED expression plasmids and the indicated miRNA. The data is relative to that measured
using a non-specific miRNA, NS. Average6standard deviation is shown. Statistically significant differences (p,0.05) between wild-type and mutant
silencing are indicated by using the one-tailed t-test. Wild-type and mutant targets are represented by green and red bars respectively. C. Increased
addition of an shRNA but not a miRNA hairpin interferes with post-transcriptional gene silencing machinery. Low levels of a GFP target plasmid and
GFP specific hairpin result in knockdown of GFP relative to a non-specific hairpin in the presence of 1 mg of empty vector, either pU6+1 or pCI_neo
(vectors which contain the promoters used to transcribe shRNA and miRNA hairpins respectively). The shRNA data is relative to that measured using a
non-specific shRNA, NS, while the miRNA data is relative to that measured using a non-specific miRNA, NS. The shR-E19 hairpin was pE19; a published
U6/shRNA expression plasmid targeting GFP (37). Average6standard deviation is shown. Each experiment was performed in triplicate.
doi:10.1371/journal.pone.0007232.g006
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element of loss-of-function of the wild-type protein contributing to
disease progression [41]. As a consequence of the allele-specific
knockdown of the mutant atxn7 gene we observed that while the
expression level of wild-type ATXN7 protein was largely
unchanged its localisation was restored to a non-aggregated, more
uniform cellular distribution. It is likely that the function of the
wild-type protein in transcriptional regulation [42–44] is inhibited
by its sequestration into aggregates, and thus reversal of this loss-
of-function may contribute to the efficacy of this therapeutic
approach. Further studies in animal models and/or patient
derived stem cells will be needed to test this hypothesis. While
targeted silencing of the mutant allele is the most ideal therapeutic
approach, two recent publications targeting the huntingtin protein
in a non-allele specific manner demonstrate therapeutic benefits in
vivo [45,46]. This may well be relevant to other polyQ disorders
such as SCA7, given the added technical challenge of allele-
specific silencing. The critical questions are the level to which the
specific wild-type protein is reduced in such a non-allele specific
approach and to what extent such loss is likely to be tolerated in
patients with a late onset neurodegenerative disease.
The identification of shRNA- and pri-miRNA-mismatched
hairpins with high selectivity for mutant atxn7 and the finding that
mutant selectivity via targeting a weak nucleotide mismatch may
have beneficial phenotypic effects through decreasing mutant
ATXN7 aggregates and restoring wild-type protein to its native
distribution pattern, suggests that selective RNAi hairpins may
have therapeutic benefits for many of the currently untreatable
polyQ disorders. Moreover, the identification of the highly
selective pri-miRNA offers a hairpin structure likely to better
tolerated [29–31] and more amenable for tissue-specific targeting
in future in vivo studies. Given that SCA7 is a neurodegenerative
disorder with a unique macular phenotype, this would provide an
ideal model for testing the efficacy of mutant-specific silencing in
patients using an RNAi-based allele-specific silencing approach.
Materials and Methods
Plasmid construction
Construction of shRNA-expressing vectors has been previously
described [47]. All expected shRNA duplexes targeting the G.A
SNP in atxn7 are indicated in Figure 1A and Figure S1A.
Construction of miRNA-based vectors has been described [32].
All expected miRNA duplexes targeting the G.A SNP in atxn7
are indicated in Figure 6. Short target sequences of the atxn7
transcript were cloned into psiCHECK (Promega) that expresses
the Renilla luciferase reporter gene (Figure 1B). Seventy-four bp of
annealed DNA oligonucleotides harbouring each of the target
sequences and NotI and XhoI sticky ends were ligated into the
psiCHECK plasmids downstream of the Renilla reporter gene.
Full-length atxn7 cDNA constructs (wild-type (CAG)10 and mutant
(CAG)100) were fused to the N-terminus of the reporter gene,
enhanced green fluorescent protein (eGFP), kindly obtained from
A Brice [28]. Mutant atxn7 (CAG)100 (also obtained from A Brice)
was modified to replace the G residue of the SNP (rs3774729) with
the mutant A allele. Long oligonucleotides were annealed and
subjected to an initial primer extension with taq polymerase; this
was followed by a secondary primer extension to produce XhoI and
HindIII sticky ends. The resultant 150 bp dsDNA cassette
harbouring the A allele with XhoI and HindIII ends was cloned
into the mutant vector (CAG)100 linearised with XhoI and HindIII.
The generated (atx7-100-A-eGFP) A allele was confirmed by DNA
sequencing. For the heterozygous assay, the mutant atx7-100-A-
eGFP was modified to substitute the eGFP gene with the red
fluorescent protein from pDsRED-monomer-N1 vector (Clon-
tech). pDsRED-monomer-N1 was linearised with HpaI and Age
and the resulting dsRED fragment was cloned into the atx7-100-
A-eGFP vector which had been linearised with the same
restriction endonucleases to remove the eGFP gene. The sequence
of the mutant vector (atx7-100-A-DsRED) was confirmed.
pDsRED-monomer-N1 was chosen because it does not result in
aggregate formation as other DsRED protein has been shown to,
therefore any aggregate formation is as a result of the fused target
protein [48]. siRNAs were a kind gift from Novartis.
Cell culture and transfections
HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, L-glutamine
(4 mM), penicillin (50 IU/ml), and streptomycin (50 mg/ml).
Plasmid transfections using the luciferase targets were performed
using Lipofectamine 2000 (Invitrogen), according to manufactur-
er’s instructions, in 24 well plates with a total of 1 mg of DNA in a
1:1 ratio of target:shRNA vector. Transfections for the hemizygous
full-length target fluorescence assays were performed using jetPEI
(Polyplus) with an N/P ratio of 5, using a total of 2 mg of DNA in a
1:1 ratio of target:shRNA vector. The use of HEK293 cells for this
assay was validated by the fact that endogenous levels of atxn7 are
insignificant in comparison to the expression of polymerase II
driven expression targets, with a greater than 500 fold increase in
atxn7 transcript in transfected cells compared to untransfected cells
(data not shown). siRNA transfections were carried out with a final
concentration of 50 nM in 24 well plates, using a total of 1 mg of
target DNA, and transfected with 2 ml of jetPEI, in an attempt to
replicate those conditions described above. Heterozygous assays
using shRNAs were performed as above except using 6-well plates
and a total of 6 mg of DNA. In cases where target vectors were
transfected separately for comparison in the heterozygous
experiments, pTZU6+1 was included to equate the total amount
of DNA transfected to that in the co-transfections of both targets.
Transfections of miRNAs in the heterozygous conditions were
performed as above except using a ratio of 2:1 of target to vector in
order to compensate for saturation of the polymerase II
transcription machinery. Competition assays were performed by
transfecting 50 ng of GFP target vector (pGFPmax, Amaxa) and
50 ng of shR-E19. A total of 1 mg of additional plasmid DNA was
transfected in the following manner; for the shRNA assay: 1 mg
pU6+1; or 0.5 mg pU6+1 and 0.5 mg shR-P16; or 1 mg shR-P16.
GFP expression in each was normalised to shR-NS with 1 mg
pU6+1. For the miRNA assay the following amounts of DNA were
added: 1 mg pCI_neo; or 0.5 mg pCI_neo and 0.5 mg miR-P16; or
1 mg miR-P16. Transfections were performed in a 24 well plate
using the same number of cells and N/P ratio as described above.
Luciferase assay
The activities of Renilla and firefly luciferase were measured
48 hours after transfection with the dual luciferase assay kit
(Promega, WI) and using the Veritas dual injection luminometer
(Turner BioSystems, Sunnyvale, CA).
Fluorescence imaging and quantification
Fluorescence was quantified using the Optima software program
on an Optima FLUOSTAR fluorimeter. All hemizygous quanti-
tative experiments were performed by normalizing to 100 mg/ml
of protein using the Micro BCA Protein Kit (Pierce, USA)
extracted 48 hours after transfection. Average values are shown
from experiments in biological triplicate with values from
indicated U6/shRNA expression plasmids normalized to a miss-
targeted shRNA expression plasmid set at 1. This was compared to
an empty U6 vector to ensure that the non-specific sequence had
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no effect on levels of target expression (data not shown). Error bars
indicate variation between experiments as the standard deviation
of the mean. For the hemizygous experiments and the competition
assay, equivalent quantities of mock-transfected cells seeded in 24-
well plates were used to subtract the background fluorescence.
Both eGFP and DsRed have an excitation wavelength 489 nm
and 556 nm respectively; and emission of 508 nm and 586 nm
respectively (Clontech). In measuring the fluorescence dual assay
of eGFP and DsRed an overlap can occur and influence the
fluorescent measurements of both. In order to avoid the overlap of
green and red fluorescence in a dual heterozygous assay,
modifications were made to the previously described assay. Firstly
the excitation and emission wavelengths for both proteins were
adjusted to create minimal overlap, such that eGFP and DsRed
were read at excitation wavelengths of 485 nm and 544 nm
respectively; and emissions of 520 nm and 590 nm respectively.
Secondly because the overlap cannot be completely removed,
equivalent quantities of cells transfected with 0.5 ug atxn7-10-G-
eGFP +1.5 mg of pTZU6+1 were used as the background values
whilst reading through the red channel. Conversely, equivalent
quantities of cells transfected with 0.5 ug atxn7-100-A-DsRED
+1.5 mg of pTZU6+1 were used as the background values whilst
reading through the green channel. Protein was extracted after
72 hours and concentrations of 200 mg/ml of protein were assayed
to maximise the level of reporter gene expression. shR-E19 is a
U6/shRNA expression plasmid targeting eGFP, a kind gift from Y
Yokobayashi [49]. Representative images shown were taken on a
ZEISS confocal microscope and the data analyzed by the ZEISS
LSM 4.1 software.
Aggregate counting
Aggregate-containing cells were counted as previously shown
[50] with the following modifications. Cells were co-transfected in
triplicate as described in the heterozygous assay. Non-overlapping
frames of live cells from each well were captured on an AxioVision
Inc. microscope using the AxioVision 4.6.3 software after
72 hours. The sum of the total number of cells in three frames
was calculated using a 406 objective. Cells with aggregates and
those with dispersed patterns of expression were counted as a total
of the three different frames of live cells. This was performed in
triplicate with the mean representing the average number of that
biological triplicate. It is noted that previous studies using the
tagged vectors had shown that the reporter genes had no effect on
the localisation and expression pattern of the ATXN7 protein
[28].
Statistical Analysis
Statistical analysis utilized two-tailed t-tests, unless otherwise
stated. Statistical differences were considered significant when the
two-tailed p value,0.05 using a paired t-test.
Supporting Information
Figure S1 Analysis of series of double mismatched shRNA guide
sequences targeting the G.A SNP in atxn7. (A) Relative levels of
Renilla luciferase (hRluc) expression normalized to firefly
luciferase (hFluc) expression measuring both the wild-type (atx7-
G-luc) and mutant (atx7-A-luc) target knockdown. (B) Quantita-
tion of fluorescence in HEK293 cells transfected with wild-type
(atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plas-
mids and the indicated shRNA. The shR-E19 hairpin was pE19; a
published U6/shRNA expression plasmid targeting eGFP (37).
Each experiment was performed in triplicate and the data is
relative to that measured using a non-specific shRNA, NS.
Average6standard deviation is shown. Statistically significant
differences (p,0.05) between wild-type and mutant silencing are
indicated by corresponding p values. Relative expression of wild-
type and mutant targets is represented by red and blue bars
respectively.
Found at: doi:10.1371/journal.pone.0007232.s001 (1.87 MB EPS)
Figure S2 Additional mismatches to the atxn7 SNP. A)
Convention for the diagram follows Schwarz et al. (2006) (16).
Sequences of predicted mismatch guide strands (underlined)
processed from an shRNA format indicating the site of the
primary mismatch to the G allele of the wild-type atxn7 target.
Functional asymmetry was induced by creating GU mis-pairings
in the 39 end of the anti-guide strand; these are highlighted in bold.
The shRNAs were labelled according to the position of the
primary mismatch relative to the 59 end of the guide strand;
followed by any additional mismatches. The nomenclature is
based on a 21bp guide strand after cleavage of the anti-sense
strand by Dicer. (B) Full-length hemizygous assay. Quantitation of
fluorescence in HEK293 cells transfected with wild-type (atx7-10-
G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and
the indicated shRNA. Each experiment was performed in
triplicate and the data is relative to that measured using a non-
specific shRNA, NS. The anti-eGFP shRNA used was pE19; a
published U6/shRNA expression plasmid targeting eGFP (37).
Average6standard deviation is shown. Wild-type and mutant
targets are represented by red and blue bars respectively.
Found at: doi:10.1371/journal.pone.0007232.s002 (1.34 MB EPS)
Figure S3 Pri-miRNAs targeting the atxn7 G.A SNP in a full-
length hemizygous assay. Quantitation of fluorescence in HEK293
cells transfected with wild-type (atx7-10-G-eGFP) or mutant (atx7-
100-A-eGFP) expression plasmids and the indicated shRNA and
miRNA. Each experiment was performed in triplicate and the
shRNA data is relative to that measured using a non-specific
shRNA, NS, while the miRNA data is relative to that measured
using a non-specific miRNA, NS. The shR-E19 hairpin was pE19;
a published U6/shRNA expression plasmid targeting eGFP (37).
Average6standard deviation is shown. Statistically significant
differences (p,0.05) between wild-type and mutant silencing are
indicated by corresponding p values. Wild-type and mutant targets
are represented by red and blue bars respectively.
Found at: doi:10.1371/journal.pone.0007232.s003 (9.64 MB EPS)
Figure S4 Knockdown of targets in a hemizygous assay using
shRNAs. Quantification of fluorescence in HEK293 cells
transfected with mutant atx7-100-G-eGFP or mutant atx7-100-
A-DsRED expression plasmids represented by blue or red bars
respectively. The indicated hairpin is shown. Each experiment was
performed in triplicate and the data is relative to that measured
using a non-specific shRNA, NS. The shR-E19 hairpin was pE19;
a published U6/shRNA expression plasmid targeting eGFP (37).
Average6standard deviation is shown. Statistically significant
differences (p,0.05) between wild-type and mutant silencing are
indicated.
Found at: doi:10.1371/journal.pone.0007232.s004 (0.98 MB EPS)
Figure S5 Comparison of siR-P16 and shR-P16 targeting the
atxn7 G.A SNP in a full-length hemizygous assay. Quantitation
of fluorescence in HEK293 cells transfected with wild-type (atx7-
10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids
and the indicated small RNA is shown. Each experiment was
performed in triplicate and the data is relative to that measured
using a non-specific shRNA, NS or siRNA, NS. The siR-eGFP is
an siRNA with specificity for eGFP. Average6standard deviation
is shown. Statistically significant differences (p,0.05) between
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wild-type and mutant silencing are indicated by corresponding p
values.
Found at: doi:10.1371/journal.pone.0007232.s005 (0.83 MB EPS)
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